- Home
- XERS vs JQC Comparison
XERS vs JQC Comparison
Compare XERS & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- JQC
- Stock Information
- Founded
- XERS 2005
- JQC 2003
- Country
- XERS United States
- JQC United States
- Employees
- XERS N/A
- JQC N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- JQC Finance Companies
- Sector
- XERS Health Care
- JQC Finance
- Exchange
- XERS Nasdaq
- JQC Nasdaq
- Market Cap
- XERS 752.7M
- JQC 730.7M
- IPO Year
- XERS 2018
- JQC N/A
- Fundamental
- Price
- XERS $5.29
- JQC $5.42
- Analyst Decision
- XERS Strong Buy
- JQC
- Analyst Count
- XERS 6
- JQC 0
- Target Price
- XERS $6.25
- JQC N/A
- AVG Volume (30 Days)
- XERS 2.2M
- JQC 714.6K
- Earning Date
- XERS 08-07-2025
- JQC 01-01-0001
- Dividend Yield
- XERS N/A
- JQC 11.13%
- EPS Growth
- XERS N/A
- JQC N/A
- EPS
- XERS N/A
- JQC N/A
- Revenue
- XERS $222,551,000.00
- JQC N/A
- Revenue This Year
- XERS $35.03
- JQC N/A
- Revenue Next Year
- XERS $18.31
- JQC N/A
- P/E Ratio
- XERS N/A
- JQC N/A
- Revenue Growth
- XERS 29.88
- JQC N/A
- 52 Week Low
- XERS $2.10
- JQC $4.82
- 52 Week High
- XERS $6.07
- JQC $5.65
- Technical
- Relative Strength Index (RSI)
- XERS 62.91
- JQC 58.06
- Support Level
- XERS $5.00
- JQC $5.45
- Resistance Level
- XERS $5.49
- JQC $5.51
- Average True Range (ATR)
- XERS 0.24
- JQC 0.03
- MACD
- XERS 0.08
- JQC 0.00
- Stochastic Oscillator
- XERS 79.38
- JQC 66.67
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.